For example, combining platycodin D with everolimus (an mTOR inhibitor) effectively inhibited survival pathway reactivation, a frequent cause of mTOR therapy failure.44 Similarly, DCZ3112 has been shown to work synergistically with trastuzumab, enhancing its effect in resistant HER2-positive models.57 Beyond targeted agents, these disruptors may also be paired with standard chemotherapies to increase apoptosis and suppress tumor cell proliferation. Here, ERBB2 is linked to neoplasm.